Blue Matter Blog

Blue Matter Breakfast Club Meeting #3 – A Discussion with Theresa Heggie of Alnylam Pharmaceuticals
November 8, 2019

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The third Breakfast Club meeting was on 5th November 2019 at Skylounge restaurant in Zug, Switzerland.  …

Blue Matter Ranked as One of the 25 Best Consulting Firms to Work for in Europe; Ranked #1 in Overall Business Outlook
September 24, 2019

About a month ago, we reported that Blue Matter was ranked as one of the Top 50 consulting firms to work for in North America (#30).  Obviously, we were excited about that.  Today, Vault released its rankings for Europe.  We’re thrilled to announce that we were ranked #12 among the best firms to work for …

Oncology Trends Part III: Critical Capabilities For a Successful Future
September 5, 2019

Future Trends In Parts I and II of this series, we reviewed the dramatic diagnostic and pharmaceutical advances over the past 5 years that have rapidly enhanced the standard of care, leading to significant and essentially curative outcomes for some patients. In this article, we discuss the near-term future – the possibilities as well as …

They Did It! Blue Matter Team Completes the South Coast Challenge.
September 4, 2019

This past weekend (31 August – 1 September), a team from Blue Matter took part in the South Coast Challenge to help raise money for cancer research.  Zeren Kocak, Linah Richer, Anwen Brown, Nafees Masri, Mariah Peixoto, and Magda Palczynska put on their hiking shoes and hit the trail to raise funds for Cancer Research …

Seven Keys to Success in Europe
August 26, 2019

For US-based biopharmaceutical companies seeking to expand, establishing a presence in Europe is usually an obvious next step.  Investors typically expect that a company will avail itself of such a large market opportunity and unlock the full commercial value of its assets. Europe represents the second largest market in the world for prescription pharmaceuticals.  The …

Blue Matter Ranked as One of the 50 Best Consulting Firms to Work for in North America
August 20, 2019

We are very excited to report that Blue Matter has joined the Vault Consulting 50 for 2020, earning a ranking as one of the 50 best consulting firms to work for in North America.  This was our first year participating in Vault’s annual survey.  Among all consulting firms surveyed, Blue Matter ranked #30.  Among boutique …

Blue Matter Team Gets Ready to Walk the South Coast to Raise Money for Cancer Research
July 25, 2019

The weekend of 31 August – 1 September will be a busy one for Blue Matter team members Zeren Kocak, Linah Richer, Anwen Brown, Nafees Masri, Mariah Peixoto, and Magda Palczynska.  They’ll be putting on their hiking shoes and taking part in this year’s South Coast Challenge to help raise money for cancer research. The …

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part II, Unmet Needs & Future Advancements
July 16, 2019

In Part I of this series, we identified and described four key trends in oncology: Novel Drug Targets and Classes of Therapy Novel Drug Designs Tumor Biology-Based Regimens Diagnostic-Driven, Adaptive Regimens: Precision Medicine Despite the significant advances these trends represent, much unmet need remains in oncology. In this installment, we outline some of those key …

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part I, Trends Overview
July 8, 2019

Over the past 5 years, several ground-breaking advancements in oncology have dramatically advanced the standard of care. These new classes of drugs include the PD(L)1 checkpoint inhibitors, the PARP inhibitors, and the EGFR resistance targeted drugs.  Also included is a general trend towards more precise and targeted treatment decisions, driven by incorporating molecular tests and …

Blue Matter Breakfast Club 2, Nick Leschly, CEO of bluebird bio
Blue Matter Breakfast Club Meeting #2 – A Discussion with Nick Leschly, CEO of bluebird bio
July 1, 2019

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The second Breakfast Club meeting was on 17th June 2019 at Skylounge restaurant in Zug, Switzerland.  The …